Literature DB >> 10717537

Current epidemiology of human plague in Madagascar.

S Chanteau1, M Ratsitorahina, L Rahalison, B Rasoamanana, F Chan, P Boisier, D Rabeson, J Roux.   

Abstract

From 1996 to 1998, 5,965 patients with suspected plague were identified in 38 districts of Madagascar (40% of the total population are exposed). Using standard bacteriology, 917 of them were confirmed or presumptive (C + P) cases. However, more than 2,000 plague cases could be estimated using F1 antigen assay. Two out of the 711 Yersinia pestis isolates tested were resistant to chloramphenicol and to ampicillin (both isolates found in the harbour of Mahajanga). Urban plague (Mahajanga harbour and Antananarivo city) accounted for 37.4% of the C + P cases. Bubonic plague represented 97.2% of the cases, and the lethality rate was still high (20%). In comparing the exposed population, plague was more prevalent in males (M:F sex ratio 1.3:1) and patients under 20 years (2.7% babies under two years). Buboes were mainly localised in the inguinal/femoral regions (55.8%). The epidemiological risk factors are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717537     DOI: 10.1016/s1286-4579(00)00289-6

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  26 in total

Review 1.  Resistance of Yersinia pestis to antimicrobial agents.

Authors:  Marc Galimand; Elisabeth Carniel; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  Emergence, spread, persistence and fade-out of sylvatic plague in Kazakhstan.

Authors:  Lise Heier; Geir O Storvik; Stephen A Davis; Hildegunn Viljugrein; Vladimir S Ageyev; Evgeniya Klassovskaya; Nils Chr Stenseth
Journal:  Proc Biol Sci       Date:  2011-02-23       Impact factor: 5.349

3.  Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.

Authors:  David R Lonsway; Sandra K Urich; Henry S Heine; Sigrid K McAllister; Shailen N Banerjee; Martin E Schriefer; Jean B Patel
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

4.  Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Authors:  Bei Li; Chunhong Du; Lei Zhou; Yujing Bi; Xiaoyi Wang; Li Wen; Zhaobiao Guo; Zhizhong Song; Ruifu Yang
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

5.  Yersinia pestis antibiotic resistance: a systematic review.

Authors:  Chen Lei; Suresh Kumar
Journal:  Osong Public Health Res Perspect       Date:  2022-02-18

6.  Epidemiologic features of four successive annual outbreaks of bubonic plague in Mahajanga, Madagascar.

Authors:  Pascal Boisier; Lila Rahalison; Monique Rasolomaharo; Maherisoa Ratsitorahina; Mahafaly Mahafaly; Maminirana Razafimahefa; Jean-Marc Duplantier; Lala Ratsifasoamanana; Suzanne Chanteau
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

7.  Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

Authors:  Claire A Cornelius; Lauriane E Quenee; Katie A Overheim; Frederick Koster; Trevor L Brasel; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2008-09-15       Impact factor: 3.441

8.  Correlates of environmental factors and human plague: an ecological study in Vietnam.

Authors:  Hau V Pham; Dat T Dang; Nguyen N Tran Minh; Nguyen D Nguyen; Tuan V Nguyen
Journal:  Int J Epidemiol       Date:  2009-07-07       Impact factor: 7.196

Review 9.  Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections.

Authors:  Fern Findlay; Lorna Proudfoot; Craig Stevens; Peter G Barlow
Journal:  Pathog Glob Health       Date:  2016-06-17       Impact factor: 2.894

10.  A decade of plague in Madagascar: a description of two hotspot districts.

Authors:  Sitraka Rakotosamimanana; Daouda Kassie; François Taglioni; Josélyne Ramamonjisoa; Fanjasoa Rakotomanana; Minoarisoa Rajerison
Journal:  BMC Public Health       Date:  2021-06-10       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.